Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now     
Bio B2BSofiva Genomics 〉Oligonucleotide array-comparative genomic hybridization analysis test

Oligonucleotide array-comparative genomic hybridization analysis test

Oligonucleotide array-comparative genomic hybridization analysis test

It is indeed exciting with nervous to welcome the newborn baby. However it is not guaranteed to have each baby born healthy even with the advanced technologies nowadays; some rare diseases such as Prader-Willi syndrome, Angelman syndrome, etc. are difficult to be detected by chromosome analysis test which is a traditional method.

Now, SOFIVA provides oligonucleotide array-comparative genomic hybridization analysis test to detect microdeletion/microduplication with updated and sophisticated method to make up the shortage of chromosome analysis test and thus enhance the prenatal/postnatal checking.

Request for Collaboration
Oligonucleotide array-comparative genomic hybridization analysis test (CGH) is the most powerful and progressive genome technique that allows the detection of losses and gains in chromosome copy number across the entire genome without prior knowledge of specific chromosomal abnormalities. With the more specific probes which are to detect the position of a specific gene, the more subtle changes in genetic material can be seen.
With a known standard sample fluorescence of different colors, respectively, designed in the wafer after the reaction with different fluorescence intensities to determine the increase or decrease in the gene and then get results by the comparison of distinction.
Comparing to traditional chromosome analysis test which takes up to 3 weeks to culture and expand the fetal cells, Array CGH technology provides more comprehensive, accurate and fast alternative for prenatal diagnosis of chromosome disease.
SOFIVA advantages
1. Comply with International standard cell gene chip Alliance (ISCA) standards
2. Provide fast, high accuracy and high resolution by using Oligo Array
3. Build database more than 15,000 people in Taiwan

I. Expectant mother / prenatal check
You can consider checking by the villi, amniotic fluid or umbilical cord blood at prenatal stage:
1. Who aged above 34.
2. Who wants to reduce the risk of pregnancy.
3. Who wants to get further diagnosis after knowing abnormality of traditional chromosome and fetal ultrasound.
4. Who has a family history of congenital abnormalities or conceives congenital anomalies baby.
II. Newborn / postnatal check
You can consider checking by cord blood, baby blood if found having the following conditions after the baby is born:
1. Who has multiple congenital anomalies
2. Who has developmental delay
3. Who has mental retardation
4. Who has abnormal appearance
Collaboration Options
Discuss with your doctor and fill the consent form as well.
Go hospitals to collect specimen (3c.c. in EDTA tube) and it will be sent back to the lab by the hospitals.
Laboratory testing and analysis. Please be patient for the report.
The report will be given in 14 working days. Further explanation and consultant will be given by your doctor.
People who like this also like
  • Phytosensulin® tablePhytosensulin® table
  • Ochratoxin/ Aflatoxin Test KitOchratoxin/ Aflatoxin Test Kit
  • ChlorzoxazoneChlorzoxazone
  • MonoStereo 3D endoscopic systemMonoStereo 3D endoscopic system
  • U-Motion II™U-Motion II™
  • NanoQ Coenzyme Q10 ProductsNanoQ Coenzyme Q10 Products
  • Facial Dermal ImplantFacial Dermal Implant
  • Non-Invasive Prenatal Screening+, NIPS+Non-Invasive Prenatal Screening+, NIPS+
  • GB KIWI e2000GB KIWI e2000
  • Digital StethoscopeDigital Stethoscope